respiratory
Lung cancer

Immune therapy benefits confirmed in NSCLC


Overall survival is doubled in patients with metastatic NSCLC  treated with pembrolizumab in combination with chemotherapy compared to chemo alone, a phase 3 trial has shown. In findings released at the American Association for Cancer Research (AACR) annual meeting in Chicago, the KEYNOTE-189 study showed significant benefits for pembrolizumab combined with pemetrexed and a platinum-based drug ...

Already a member?

Enter your email to keep reading.


OR